Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy.

  PMID 33723257 · PMC7961017 · Nature communications · 2021 · 7 claims · 7 setups

  Has reproduction · 70

  Proportions of activated and proliferating CD8+ T cells (cluster C16/activated EM) are significantly higher in responders before and during therapy

  pbmc cd3+cd8+ pbmc-derived metastatic high-dimensional single-cell polychromatic

• TOPK Suppresses the CD8(+) T Cell Antitumor Immunity via Modulation of IRF5 Expression.

  PMID 41868885 · PMC13003159 · Cancer communications (London, England) · 2026 · 8 claims · 8 setups

  Full-text index only

  A TOPK+ subset of tumor-infiltrating CD8+ T cells exists in melanoma at higher frequency than in normal lymph nodes and shows suppressed cytotoxic/cytokine programs.

  tumor-infiltrating melanoma b16-f10 unspecified scrna-seq flow multiplex

• Lymphodepleting preconditioning impairs host antitumor immunity induced by adoptive T cell therapy in mouse models.

  PMID 41912536 · PMC13172322 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  ACT with TCR-transgenic (OTI) CD8+ T cells eradicates established B16F10-OTI tumors and expands host CD8+ T cells with tumor-reactive (PD-1+GzmB-/PD-1+GzmB+, Tpex/Tex) and tissue-resident phenotypes

  b16f10-oti draining ragko c57bl flow tumor antibody

• PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.

  PMID 33188038 · PMC7668369 · Journal for immunotherapy of cancer · 2020 · 7 claims · 6 setups

  Has reproduction · 75

  The frequency of circulating PD-1+TIGIT+ (DPOS) CD8+ T cells after 1 month of anti-PD-1 therapy is associated with clinical response and overall survival

  pbmcs sorted expanded cancer multiparameter receptor targeted

• T cell-intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses.

  PMID 41837284 · PMC12987620 · The Journal of clinical investigation · 2026 · 8 claims · 8 setups

  Full-text index only

  Loss of T cell-intrinsic VISTA enhances early priming and short-term expansion of CD8+ T cells but this initial advantage fails to confer durable tumor control

  tumor vsir cell-specific myeloid-specific flow adoptive peptide

• Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75.

  PMID 7642699 · PMC2199968 · The Journal of cell biology · 1995 · 7 claims · 7 setups

  Full-text index only

  The 36-amino acid cytoplasmic tail of gp75 alone is sufficient to direct intracellular retention and targeting of chimeric CD8 proteins to the endosomal/lysosomal compartment in fibroblasts

  melanoma sk-mel-19 immunoprecipitated coli immunofluorescence immunoelectron protease

• Phased differentiation of γδ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers.

  PMID 34721945 · PMC8555559 · Oncoimmunology · 2021 · 7 claims · 6 setups

  Has reproduction · 44

  In tumors, TCRVγnon9 γδ T cells (the majority γδ TIL subset) are quantitatively correlated and aligned with T CD8 cells for differentiation, exhaustion, gene expression profile, and response to immune checkpoint therapy

  pbmc tumor syngeneic scrnaseq cite-seq flow

• Machine learning-based identification of an immunotherapy-related signature to enhance outcomes and immunotherapy responses in melanoma.

  PMID 39355255 · PMC11442245 · Frontiers in immunology · 2024 · 8 claims · 8 setups

  Has reproduction · 69

  66 consensus immunotherapy prognostic genes (CITPGs) were identified from the intersection of WGCNA modules, immunotherapy responder-vs-non-responder DEGs, and tumor-vs-normal DEGs

  melanoma tcga-skcm prjeb23709 microarray wgcna differential consensus

• Tumor reactivity assessment using clonal expression reveals tumor reactive CD8(+) T cell heterogeneity across solid tumors.

  PMID 42079667 · PMC13128579 · Frontiers in immunology · 2026 · 8 claims · 5 setups

  Full-text index only

  TRACE, a clonotype-level CD8+ TRT classifier trained on an aggregated multi-study dataset, achieves robust holdout performance (mean MCC 0.84, F1 0.85)

  cd8+ expanded aggregated combined scrna-seq co-culture gene

• The ubiquitin ligase KLHL6 drives resistance to CD8(+) T cell dysfunction.

  PMID 41535474 · PMC12979199 · Nature · 2026 · 8 claims · 8 setups

  Full-text index only

  KLHL6 is a dual-negative regulator of both T cell exhaustion and mitochondrial dysfunction

  cd8+ cas9+ sgklhl6-transduced klhl6 bulk pooled flow

• 5-HT reuptake blockade induces pyroptosis in BRAF(V600E)-mutated melanomas via remodeling histone serotonylation.

  PMID 41494533 · PMC12866116 · Cell reports. Medicine · 2026 · 8 claims · 8 setups

  Has reproduction · 40

  High-throughput screening of 90 FDA-approved antidepressants identifies PH as an alternative therapeutic for BRAF V600E-mutated melanoma

  braf a375 gfp-tph1-overexpressing yumm1.7 high-throughput ic50 xenograft

• Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy.

  PMID 42047827 · PMC13125473 · Cancer immunology, immunotherapy : CII · 2026 · 8 claims · 6 setups

  Full-text index only

  The immune-low group defined by the 107-gene immune signature includes mostly patients who do not respond to anti-PD1 inhibitors

  ffpe gem campbell targeted consensus cibersortx

• Disruption of tRNA threonylation triggers RIG-I mediated anti-tumour immune response.

  PMID 41735308 · PMC13043769 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  OSGEP is the catalytic subunit of the KEOPS complex responsible for t6A modification at position 37 of cytoplasmic tRNAs, and its loss causes the highest protein aggregation among 45 screened tRNA-modifying enzymes in melanoma cells

  mm117 b16f10 b16f10-derived c57bl esirna shrna rna-seq

• Analysis of Tumor-Infiltrating T-Cell Transcriptomes Reveal a Unique Genetic Signature across Different Types of Cancer.

  PMID 36232369 · PMC9569723 · International journal of molecular sciences · 2022 · 8 claims · 8 setups

  Has reproduction · 87

  Common genes shared across five cancer types differ from those found in nonmalignant tissue-resident T-cells for each subset (CD4-T, CD8-T, Treg)

  breast lung colorectal melanoma single-cell gene reactome

• Pharmacological perturbation of splicing elicits SMG1 reduction: Implications for cancer therapy.

  PMID 41623476 · PMC12857400 · iScience · 2026 · 7 claims · 12 setups

  Full-text index only

  Splicing-modulatory drugs MS023 and indisulam act as inadvertent NMD inhibitors by downregulating SMG1 protein levels

  4t1 tumor-draining arst panc02 mts tumor ifn-γ

• The transcription factor EHF promotes the maturation and immunosuppression of conventional dendritic cells.

  PMID 41730908 · PMC13039115 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  EHF orchestrates an immunosuppressive maturation program in cDC1s and cDC2s downstream of TLR7/8/9 sensing of self-nucleic acids

  ehf facs-sorted dss-induced lethal cd4+

• Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome.

  PMID 41956098 · PMC7619149 · Immunity · 2026 · 8 claims · 8 setups

  Full-text index only

  Reduced NMD activity (lower NMD score) predicts improved CPI response across >1,000 patients, independent of TMB or tumor type

  tcga a375 reporter patient-derived multi-omics crispr-cas9 sirna

• CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance.

  PMID 41564866 · PMC12866162 · Cell reports. Medicine · 2026 · 8 claims · 8 setups

  Full-text index only

  CHD1 and MAP3K7 loss additively sensitizes cancer cells to IFN-γ-induced death

  a375 crc-9 ht-29 vcap whole-genome autologous incucyte